CADL Candel Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1841387 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-335.6%
TTM EPS YoY-173.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-93.6%
ROA-65.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets37.7%
Debt / equity0.00x
Current ratio7.57x
Interest coverage-13.30x
Cash quality & payout
Operating cash flow / net income0.70x
Accruals ratio-19.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $15.59M | $19.80M | $9.84M | $11.03M | $8.46M | $6.99M | $4.02M | $4.82M |
| SG&A expense | $7.39M | $6.95M | $6.44M | $4.72M | $4.75M | $4.19M | $4.11M | $3.32M |
| Operating income | -$22.98M | -$26.75M | -$16.28M | -$15.75M | -$13.21M | -$11.18M | -$8.13M | -$8.14M |
| Interest expense | $1.59M | $1.57M | $1.56M | $1.42M | $161,000 | $236,000 | $306,000 | -$3.79M |
| Net income | -$21.87M | -$38.91M | -$8.86M | -$29.50M | -$11.27M | -$4.80M | $7.38M | -$14.07M |
| EBITDA | -$22.78M | -$26.55M | -$16.14M | -$15.59M | -$13.01M | -$10.98M | -$7.88M | -$7.90M |
| EPS (basic) | -0.28 | -0.52 | -0.14 | — | -0.21 | -0.09 | 0.15 | — |
| EPS (diluted) | -0.28 | -0.52 | -0.14 | — | -0.21 | -0.09 | 0.13 | — |
| Weighted avg. shares (diluted) | 77.39M | 74.13M | 62.36M | — | 54.89M | 51.49M | 54.77M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $203.12M | $201.56M | $194.83M | $119.73M | $87.23M | $100.95M | $92.43M | $102.92M |
| Current assets | $207.35M | $204.16M | $197.75M | $121.39M | $90.13M | $103.61M | $93.15M | $103.80M |
| PP&E, net | $1.90M | $2.00M | $2.08M | $1.64M | $1.36M | $1.66M | $1.97M | $2.19M |
| Total assets | $211.11M | $208.15M | $201.92M | $125.19M | $93.60M | $105.97M | $95.91M | $106.87M |
| Current liabilities | $27.39M | $12.69M | $7.05M | $9.00M | $10.93M | $14.71M | $20.07M | $37.53M |
| Short-term debt | — | — | — | $0 | $4.22M | $6.70M | $9.17M | $9.89M |
| Long-term debt | — | — | — | — | — | — | — | $1.73M |
| Total debt | — | — | — | — | — | — | — | $11.63M |
| Total liabilities | $79.52M | $82.02M | $63.89M | $73.27M | $13.47M | $15.76M | $21.23M | $40.54M |
| Shareholders' equity | $131.59M | $126.13M | $138.03M | $51.92M | $80.12M | $90.21M | $74.67M | $66.33M |
| Net debt | — | — | — | — | — | — | — | -$91.29M |
| Shares outstanding | 78.45M | 76.12M | 73.26M | 54.90M | 54.90M | 54.89M | 49.25M | 46.81M |
| Cash flow statement | ||||||||
| Operating cash flow | -$23.12M | -$17.18M | -$18.04M | -$10.57M | -$10.24M | -$8.89M | -$8.62M | -$5.81M |
| Capital expenditure | $141,000 | $69,000 | $675,000 | $409,000 | $144,000 | $31,000 | $3,000 | $3,000 |
| Free cash flow | -$23.26M | -$17.25M | -$18.71M | -$10.98M | -$10.38M | -$8.92M | -$8.62M | -$5.82M |
| Investing cash flow | -$141,000 | -$69,000 | -$675,000 | -$409,000 | -$117,000 | -$31,000 | -$3,000 | -$3,000 |
| Financing cash flow | $24.81M | $23.98M | $93.81M | $43.90M | -$3.37M | $17.44M | -$1.87M | $91.91M |
| Depreciation & amortization | $200,000 | $200,000 | $149,000 | $163,000 | $200,000 | $200,000 | $245,000 | $245,000 |
| Stock-based compensation | $2.65M | $2.86M | $1.45M | $1.29M | $1.16M | $1.05M | $314,000 | $1.24M |
Free plan shows the latest 8 periods; Pro shows all 26 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.